Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ventracor's "artificial heart" shows early promise:

This article was originally published in Clinica

Executive Summary

Ventracor has reported promising early results from a pilot trial of its "artificial heart", VentrAssist, which is designed for use in patients who are not eligible for heart transplantation and are no longer responding to optimal medical therapy. The first patient to be implanted with the device - a left ventricular assist system - has made an excellent early recovery and was discharged to his home on August 19, said the Sydney, Australia firm. The patient, who received the device in June this year, is the first of 10 patients who are taking part in the trial. The trial is being conducted at The Alfred hospital in Melbourne.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT063298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel